Clinical Trial Update: One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating three adjuvanted dose levels of a recombinant plague vaccine using rF1 and rV antigens; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plague

Drugs mentioned

• Recombinant plague vaccine (rF1 and rV antigens) (rF1 and rV antigens)

Snippet

Sponsor: PharmAthene UK Limited | Conditions: Plague | Phase 1 | Status: COMPLETED